148 related articles for article (PubMed ID: 26801792)
41. Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy.
Osorio S; Bernis C; de La Cámara R
Haematologica; 2002 Feb; 87(2):ELT05. PubMed ID: 11836182
[No Abstract] [Full Text] [Related]
42. Leukaemic presentation of angioimmunoblastic T-cell lymphoma.
Lin KW; Lee YS; Phipps C
Br J Haematol; 2014 Sep; 166(6):808. PubMed ID: 24974735
[No Abstract] [Full Text] [Related]
43. Current status of the treatment of HIV-associated lymphoma.
Kaplan LD
Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
[No Abstract] [Full Text] [Related]
44. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
Coiffier B
J Clin Oncol; 2003 Jul; 21(13):2457-9. PubMed ID: 12829662
[No Abstract] [Full Text] [Related]
45. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
46. Case report and review of immunodeficiency-associated Burkitt lymphoma.
Johnson DH; Reske T; Ruiz M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e121-5. PubMed ID: 25701328
[No Abstract] [Full Text] [Related]
47. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
48. Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction.
Chen R; Abbott BL; Myint H
Clin Adv Hematol Oncol; 2006 Nov; 4(11):841-4; discussion 844-7. PubMed ID: 17143254
[No Abstract] [Full Text] [Related]
49. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
50. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
51. [Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].
Sonneveld P; Huijgens PC; Hagenbeek A
Ned Tijdschr Geneeskd; 1999 Feb; 143(8):418-9. PubMed ID: 10221113
[TBL] [Abstract][Full Text] [Related]
52. Lymphoma in the Waldeyer ring: a great masquerader.
Osborne RF; Hamilton JS; Avitia S
Ear Nose Throat J; 2009 Jun; 88(6):954-6. PubMed ID: 19517398
[No Abstract] [Full Text] [Related]
53. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
Zheng W; Zhu J; Xie Y
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
[No Abstract] [Full Text] [Related]
54. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
[TBL] [Abstract][Full Text] [Related]
55. Chemotherapy for Hodgkin's disease.
Ekert H
N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
[No Abstract] [Full Text] [Related]
56. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
57. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
Phipps C; Lee YS; Hwang W
Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
[No Abstract] [Full Text] [Related]
58. Tumor melt: primary effusion lymphoma of the heart.
Kriekard P; Garcia JA; Nardi-Korver L; Krantz MJ
Am J Med; 2012 Sep; 125(9):e5-6. PubMed ID: 22682793
[No Abstract] [Full Text] [Related]
59. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.
Kamata M; Sugaya M; Miyagaki T; Sonoda K; Ichimura Y; Mitsui H; Sato S; Kamikubo Y; Kurokawa M
Int J Dermatol; 2014 Jan; 53(1):e24-6. PubMed ID: 23452101
[No Abstract] [Full Text] [Related]
60. Making moves: Transitioning R-EPOCH to the ambulatory setting.
Martin AL; Frank JP; Waggoner ML
J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
